COMMUNIQUÉS West-GlobeNewswire

Glaucoma 360 2026: Where Science, Innovation, and Collaboration Shape the Future of Vision
10/11/2025
Annual event accelerates progress toward curing glaucoma, from groundbreaking research to emerging therapies SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glaucoma Research Foundation (GRF) today announced the 15th [...]
HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy
10/11/2025
Washington, D.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- The U.S. Department of Health and Human Services (HHS) today announced historic action to restore gold-standard science to women’s health. After more than two decades [...]
Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
10/11/2025
New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of aprocitentan’s novel [...]
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
10/11/2025
VANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled [...]
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
10/11/2025
Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated [...]
NeXtGen Biologics and Lovell® Government Services Partner to Bring Innovative Advanced Wound Care Technology to Federal Healthcare Systems
10/11/2025
PENSACOLA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lovell ® Government Services and NeXtGen™ Biologics, Inc., a medical device company that manufactures NeoMatriX ® , announced today that they have partnered to serve [...]
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
10/11/2025
HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare [...]
Voyager Reports Third Quarter 2025 Financial and Operating Results
10/11/2025
- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small [...]
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
10/11/2025
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates [...]
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
10/11/2025
BERKELEY, Calif. and MAINZ, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of [...]
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
10/11/2025
ONE-D is the first reported protocol to achieve remission from treatment-resistant depression with a single day of treatment, using an FDA-cleared device. HOPE is one of the first Ampa deployments nationwide and is now [...]
Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference
10/11/2025
GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
10/11/2025
Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion by 2032 Vancouver, Canada, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( [...]
Arch Biopartners Arranges Non-Brokered Private Placement
10/11/2025
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc ., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has arranged a non-brokered private placement offering of 480,769 [...]
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
10/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for [...]
NewGen Announces Up to US$2 Million Share Repurchase Program
10/11/2025
The decision to initiate the program signals NewGen’s unwavering confidence in its future growth and deeply undervalued share price BANGKOK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“ [...]
BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
10/11/2025
SUNNYVALE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
10/11/2025
Data presented at the 40 th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor [...]
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
10/11/2025
Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics that make them more [...]

Pages